Michael E Johnson

List of Publications by Year
in descending order

155 papers	4,285 citations	136950 32 h-index	138484 58 g-index
159 all docs	159 docs citations	159 times ranked	5213 citing authors

#	Article	IF	Citations
1	Identification of Small Molecule Inhibitors against Staphylococcus aureus Dihydroorotase via HTS. International Journal of Molecular Sciences, 2021, 22, 9984.	4.1	6
2	MD simulations reveal alternate conformations of the oxyanion hole in the Zika virus NS2B/NS3 protease. Proteins: Structure, Function and Bioinformatics, 2020, 88, 345-354.	2.6	6
3	Cytotoxic and non-cytotoxic cardiac glycosides isolated from the combined flowers, leaves, and twigs of Streblus asper. Bioorganic and Medicinal Chemistry, 2020, 28, 115301.	3.0	14
4	Baicalein Is a Phytohormone that Signals Through the Progesterone and Glucocorticoid Receptors. Hormones and Cancer, 2020, 11, 97-110.	4.9	10
5	Na⁺/K⁺-ATPase-Targeted Cytotoxicity of (+)-Digoxin and Several Semisynthetic Derivatives. Journal of Natural Products, 2020, 83, 638-648.	3.0	23
6	Structural approaches to pathway-specific antimicrobial agents. Translational Research, 2020, 220, 114-121.	5.0	0
7	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of vraTSR Expression in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
8	Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2349-2353.	2.2	4
9	Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. Bioorganic and Medicinal Chemistry, 2019, 27, 1981-1989.	3.0	23
10	Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer, 2018, 124, 3000-3007.	4.1	40
11	Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2074-2079.	2.2	9
12	A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii. Bioorganic and Medicinal Chemistry, 2018, 26, 65-76.	3.0	16
13	Hit-to-Lead: Hit Validation and Assessment. Methods in Enzymology, 2018, 610, 265-309.	1.0	23
14	Structural characterization ofPorphyromonas gingivalisenoyl-ACP reductase II (FabK). Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 105-112.	0.8	11
15	Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2837-2841.	2.2	0
16	The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus. Hormones and Cancer, 2018, 9, 265-277.	4.9	26
17	(+)-Strebloside-Induced Cytotoxicity in Ovarian Cancer Cells Is Mediated through Cardiac Glycoside Signaling Networks. Journal of Natural Products, 2017, 80, 659-669.	3.0	33
18	Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Research, 2017, 139, 49-58.	4.1	113

#	Article	IF	Citations
19	Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers. Archives of Psychiatric Nursing, 2017, 31, 62-67.	1.4	1
20	Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development. ACS Infectious Diseases, 2017, 3, 54-61.	3.8	31
21	Evaluating thermodynamic integration performance of the new amber molecular dynamics package and assess potential halogen bonds of enoyl-ACP reductase (FabI) benzimidazole inhibitors. Journal of Computational Chemistry, 2016, 37, 836-847.	3.3	16
22	Over-expression, purification, and confirmation of Bacillus anthracis transcriptional regulator NprR. Protein Expression and Purification, 2016, 125, 83-89.	1.3	13
23	Ca-asp bound X-ray structure and inhibition of Bacillus anthracis dihydroorotase (DHOase). Bioorganic and Medicinal Chemistry, 2016, 24, 4536-4543.	3.0	18
24	Identification of B. anthracis N5-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. Bioorganic and Medicinal Chemistry, 2016, 24, 596-605.	3.0	7
25	Identification of Bacillus anthracis PurE inhibitors with antimicrobial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 1492-1499.	3.0	18
26	Comparison of radii sets, entropy, <scp>QM</scp> methods, and sampling on <scp>MMâ€PBSA</scp>, <scp>MMâ€GBSA</scp>, and <scp>QM/MMâ€GBSA</scp> ligand binding energies of <scp>F</scp>. tularensis enoylâ€<scp>ACP</scp> reductase (<scp>F</scp>abI). Journal of Computational Chemistry, 2015, 36, 1859-1873.	3.3	91
27	Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1292-1296.	2.2	18
28	Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV. ACS Chemical Biology, 2015, 10, 1456-1465.	3.4	114
29	Indole trimers with antibacterial activity against Gram-positive organisms produced using combinatorial biocatalysis. AMB Express, 2015, 5, 125.	3.0	7
30	Conformational diversity of bacterial FabH: Implications for molecular recognition specificity. Journal of Molecular Graphics and Modelling, 2015, 55, 115-122.	2.4	1
31	Structures of SAICAR synthetase (PurC) from Streptococcus pneumoniae with ADP, Mg²⁺, AIR and Asp. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 841-850.	2.5	13
32	Metabolism-directed structure optimization of benzimidazole-basedFrancisella tularensisenoyl-reductase (FabI) inhibitors. Xenobiotica, 2014, 44, 404-416.	1.1	6
33	Elucidation of the bicarbonate binding site and insights into the carboxylation mechanism of (N5)-carboxyaminoimidazole ribonucleotide synthase (PurK) fromBacillus anthracis. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 3057-3065.	2.5	2
34	Metal stopping reagents facilitate discontinuous activity assays of the de novo purine biosynthesis enzyme PurE. Analytical Biochemistry, 2014, 452, 43-45.	2.4	3
35	Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings. Bioorganic and Medicinal Chemistry, 2014, 22, 167-177.	3.0	48
36	A novel combinatorial biocatalytic approach for producing antibacterial compounds effective against Mycobacterium tuberculosis (TB). Applied Microbiology and Biotechnology, 2013, 97, 7151-7163.	3.6	6

#	Article	IF	Citations
37	A colorimetric assay optimization for high-throughput screening of dihydroorotase by detecting ureido groups. Analytical Biochemistry, 2013, 441, 87-94.	2.4	5
38	Special Challenges to the Rational Design of Antibacterial Agents. Annual Reports in Medicinal Chemistry, 2013, 48, 283-298.	0.9	6
39	Fragment-Based Drug Discovery Using a Multidomain, Parallel MD-MM/PBSA Screening Protocol. Journal of Chemical Information and Modeling, 2013, 53, 560-572.	5.4	18
40	Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis. Journal of Medicinal Chemistry, 2013, 56, 6560-6572.	6.4	215
41	High-level expression, purification, and characterization of Staphylococcus aureus dihydroorotase (PyrC) as a cleavable His-SUMO fusion. Protein Expression and Purification, 2013, 88, 98-106.	1.3	16
42	Synergistic Inhibitor Binding to the Papainâ€Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications. ChemMedChem, 2013, 8, 1361-1372.	3.2	19
43	High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes. PLoS ONE, 2013, 8, e75144.	2.5	21
44	Metabolismâ€Directed Structure Optimization of Benzimidazoleâ€Based F. Tularensis Enoylâ€Reductase (FabI) Inhibitors. FASEB Journal, 2013, 27, 664.3.	0.5	0
45	Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening. Journal of Chemical Information and Modeling, 2012, 52, 2245-2256.	5.4	12
46	Discovery of a Novel and Potent Class of F. tularensis Enoyl-Reductase (FabI) Inhibitors by Molecular Shape and Electrostatic Matching. Journal of Medicinal Chemistry, 2012, 55, 268-279.	6.4	57
47	Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis. Protein Expression and Purification, 2012, 85, 100-108.	1.3	5
48	Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 5933-5941.	6.4	20
49	Reducing agents affect inhibitory activities of compounds: Results from multiple drug targets. Analytical Biochemistry, 2012, 423, 46-53.	2.4	31
50	Comparison of SARS and NL63 Papain-Like Protease Binding Sites and Binding Site Dynamics: Inhibitor Design Implications. Journal of Molecular Biology, 2011, 414, 272-288.	4.2	23
51	Structure ofN5-carboxyaminoimidazole ribonucleotide synthase (PurK) fromBacillus anthracis. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 870-874.	2.5	2
52	Humidity control can compensate for the damage induced in protein crystals by alien solutions. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 1300-1308.	0.7	6
53	Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug Discovery Today, 2010, 15, 804-811.	6.4	102
54	Structure of dihydroorotase fromBacillus anthracisat 2.6â€...Ã... resolution. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 1432-1435.	0.7	11

#	Article	IF	Citations
55	Structure of theFrancisella tularensisenoyl-acyl carrier protein reductase (FabI) in complex with NAD⁺and triclosan. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 1436-1440.	0.7	11
56	Crystal Structure of the Nonerythroid Î±-Spectrin Tetramerization Site Reveals Differences between Erythroid and Nonerythroid Spectrin Tetramer Formation. Journal of Biological Chemistry, 2010, 285, 14572-14584.	3.4	26
57	Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Proteinâ^'Ligand X-ray Structure and Biological Evaluation. Journal of Medicinal Chemistry, 2010, 53, 4968-4979.	6.4	129
58	Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages. Journal of Antimicrobial Chemotherapy, 2009, 63, 928-936.	3.0	88
59	Glutamate Racemase Dimerization Inhibits Dynamic Conformational Flexibility and Reduces Catalytic Rates. Biochemistry, 2009, 48, 7045-7055.	2.5	16
60	Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndromeâ^'Coronavirus Papain-Like Protease. Journal of Medicinal Chemistry, 2009, 52, 5228-5240.	6.4	110
61	Design and Synthesis of Aryl Ether Inhibitors of the Bacillus Anthracis Enoylâ€ACP Reductase. ChemMedChem, 2008, 3, 1250-1268.	3.2	40
62	Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3565-3569.	2.2	31
63	Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5684-5688.	2.2	99
64	Structural model of a complex between the heterotrimeric G protein, GsÎ±, and tubulin. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 964-973.	4.1	32
65	A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16119-16124.	7.1	407
66	Structural and Functional Analysis of Two Glutamate Racemase Isozymes from Bacillus anthracis and Implications for Inhibitor Design. Journal of Molecular Biology, 2007, 371, 1219-1237.	4.2	50
67	Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5876-5880.	2.2	94
68	Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. Annual Reports in Medicinal Chemistry, 2006, 41, 183-196.	0.9	35
69	Design, Syntheis, and Evaluation of Oxyanion-Hole Selective Inhibitor Substituents for the S1 Subsite of Factor Xa.. ChemInform, 2005, 36, no.	0.0	0
70	Conformational Studies of the Tetramerization Site of Human Erythroid Spectrin by Cysteine-Scanning Spin-Labeling EPR Methodsâ€. Biochemistry, 2005, 44, 15898-15905.	2.5	16
71	Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-like Protease Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6767-6771.	6.4	114
72	Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5165-5170.	2.2	8

#	Article	IF	Citations
73	Design and synthesis of highly constrained factor Xa inhibitors: amidine-Substituted bis(benzoyl)-[and]-diazepan-2-ones and bis(benzylidene)-bis(gem-dimethyl)cycloketones. Bioorganic and Medicinal Chemistry, 2003, 11, 3379-3392.	3.0	14
74	Regioselective Covalent Modification of Hemoglobin in Search of Antisickling Agents. Journal of Medicinal Chemistry, 2003, 46, 936-953.	6.4	33
75	Structural Analysis of the Î±N-Terminal Region of Erythroid and Nonerythroid Spectrins by Small-Angle X-ray Scatteringâ€. Biochemistry, 2003, 42, 14702-14710.	2.5	28
76	Solution Structural Studies on Human Erythrocyte Î±-Spectrin Tetramerization Site. Journal of Biological Chemistry, 2003, 278, 21837-21844.	3.4	35
77	Nuclear magnetic resonance studies of mutations at the tetramerization region of human alpha spectrin. Blood, 2002, 100, 283-288.	1.4	20
78	An oxyanion-Hole selective serine protease inhibitor in complex with trypsin. Bioorganic and Medicinal Chemistry, 2002, 10, 41-46.	3.0	18
79	NMR analysis of secondary structure and dynamics of a recombinant peptide from the N-terminal region of human erythroid Î±-spectrin. FEBS Letters, 2000, 485, 81-86.	2.8	15
80	A Mass Spectrometry Screening Method for Antiaggregatory Activity of Proteins Covalently Modified by Combinatorial Library Members:â€‰ Application to Sickle Hemoglobin. ACS Combinatorial Science, 2000, 2, 314-317.	3.3	6
81	Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 1999, 43, 2404-2408.	3.2	200
82	Structure-based design and synthesis of novel thrombin inhibitors based on phosphinic peptide mimetics. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1957-1962.	2.2	12
83	1H, 15N, and 13C NMR backbone assignments of the N-terminal region of human erythrocyte alpha spectrin including one structural domain. Journal of Biomolecular NMR, 1999, 15, 345-346.	2.8	8
84	Comparative molecular modeling analysis ofÂ5-amidinoindole and benzamidine binding to thrombin and trypsin: specific H-bond formation contributes to high 5-amidinoindole potency and selectivity for thrombin and factor Xa. , 1999, 12, 235-241.		12
85	Isolation, stereochemical assignments and molecular mechanics calculation of ethyl Î²-l-arabinopyranoside. Carbohydrate Research, 1998, 311, 85-88.	2.3	4
86	Extraordinary Formation of a Novel Butadiene Derivative, (Z,E)-1-(2-Naphthylmethyloxycarbonyl-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 (E,E)-Isomer. Journal of Organic Chemistry, 1998, 63, 7516-7519.	3.2	1
87	Crystal Structure of a 1:1 Complex of Natural Diterpenoids:Â Absolute Configurations and Unambiguous NMR Spectral Assignments of Neoangustifolin and Epinodosinol. Journal of Natural Products, 1997, 60, 203-206.	3.0	28
88	Antagonistic Properties of Centrally Truncated Analogs of [d-Trp32]NPY. Journal of Medicinal Chemistry, 1996, 39, 1142-1147.	6.4	6
89	Synthesis, Structure, and Antagonistic Properties of des-Asn 29 [d -Trp 28,32]NPY(27â€“36). Peptides, 1996, 17, 1113-1118.	2.4	3
90	Photoaffinity labelling of cyanomethaemoglobin with derivatives of tryptophan and 5-bromotryptophan. Biochemical Journal, 1995, 308, 251-260.	3.7	5

#	Article	IF	Citations
91	Oxidation of Certain 4-Substituted Phenethyl Alcohols with Collins Reagent: On the Mechanism of a Carbon-Carbon Bond Cleavage. Synthetic Communications, 1995, 25, 533-537.	2.1	21
92	Proposed cation-Ï€ mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition. FEBS Letters, 1995, 370, 1-5.	2.8	38
93	Amino Acid and Peptide Approaches to Anti-sickling Agents. Current Medicinal Chemistry, 1995, 1, 418-422.	2.4	0
94	Probabilistic Approach to NMR-Based Determination of Accurate Local Conformation and Three-Dimensional Structure of Proteins in Solution. ACS Symposium Series, 1994, , 446-465.	0.5	0
95	Comparison of Protein Structures in Solution Using Local Conformations Derived from NMR Data: Application to Cytochromec. Journal of Biomolecular Structure and Dynamics, 1994, 12, 527-558.	3.5	15
96	An efficient synthesis of 5-azidotryptophan. Tetrahedron Letters, 1994, 35, 6255-6258.	1.4	15
97	Conformational rearrangements required of the V3loop of HIV-1 gp120 for proteolytic cleavage and infection. FEBS Letters, 1994, 337, 4-8.	2.8	31
98	Computer Software Reviews. InStat, Version 2.0 for DOS. Journal of Chemical Information and Computer Sciences, 1994, 34, 682-682.	2.8	0
99	CONFORMATIONAL ANALYSIS OF CYCLOTHEONAMIDE A AND ITS INTERACTIONS WITH THROMBIN. Protein and Peptide Letters, 1994, 1, 9-14.	0.9	4
100	Molecular dynamics of sickle and normal hemoglobins. Biopolymers, 1993, 33, 735-742.	2.4	11
101	NMR assignments and conformational analysis of yuanhuacin. Magnetic Resonance in Chemistry, 1993, 31, 194-199.	1.9	5
102	Assignment of the1H and13C NMR spectra of the C21 steroids 12-Î²-O-acetyltenacigenin A and tenacigenin A by two-dimensional NMR techniques and computer modeling. Magnetic Resonance in Chemistry, 1993, 31, 215-221.	1.9	19
103	Design and synthesis of a bicyclic non-peptide Î²-bend mimetic of enkephalin. Tetrahedron, 1993, 49, 3489-3500.	1.9	10
104	A novel dimerization of ethyl 3-cyanomethyl-2-indolecarboxylate. Tetrahedron Letters, 1993, 34, 3215-3218.	1.4	5
105	Design and synthesis of hypertrehalosemic hormoe mimetics. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 1277-1282.	2.2	5
106	Nonpeptide Î²-turn mimetics of enkephalin. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 835-840.	2.2	11
107	Polyoxypregnanes from Marsdenia tenacissima. Phytochemistry, 1993, 34, 1615-1620.	2.9	87
108	A New Synthesis of 5-Bromo-DL-tryptophan. Synthetic Communications, 1993, 23, 2011-2017.	2.1	10

#	Article	IF	Citations
109	3-(Carbazol-2-yl)- and 3-(Carbazol-3-yl)-dl-alanines. Synthetic Communications, 1993, 23, 2435-2442.	2.1	3
110	Derivation of locally accurate spatial protein structure from NMR data. Progress in Biophysics and Molecular Biology, 1993, 59, 285-339.	2.9	33
111	Cytotoxic and Antimalarial Bisbenzylisoquinoline Alkaloids from Cyclea barbata. Journal of Natural Products, 1993, 56, 22-29.	3.0	76
112	Peptide Turn Mimetics. , 1993, , 366-378.		1
113	Peptide mimetics of the thrombin-bound structure of fibrinopeptide A.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1705-1709.	7.1	28
114	Bivalent-metal binding to CheY protein. Effect on protein conformation. Biochemical Journal, 1992, 287, 521-531.	3.7	22
115	Specificity and affinity of binding of phosphate-containing compounds to CheY protein. Biochemical Journal, 1992, 287, 533-543.	3.7	8
116	Design, synthesis and conformational analysis of Î³-turn peptide mimetics of bradykinin. Biochemical and Biophysical Research Communications, 1992, 187, 999-1006.	2.1	46
117	Location of potential binding sites on deoxy hemoglobin for the design of antigelling agents. Journal of Molecular Biology, 1992, 223, 791-800.	4.2	10
118	Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5872-5876.	7.1	79
119	Estimation of accuracy in determining protein backbone conformations from NOE data and empirical Ï†, Ïˆ probability distributions. Journal of Magnetic Resonance, 1992, 96, 457-472.	0.5	1
120	Nâ€¹ and Câ€² substituted tryptophans as potential inhibitors of sickle cell hemoglobin gelation. Journal of Heterocyclic Chemistry, 1992, 29, 335-341.	2.6	12
121	Examination of HIV-1 protease secondary structure specificity using conformationally constrained inhibitors. Journal of Medicinal Chemistry, 1991, 34, 3395-3399.	6.4	19
122	Design and synthesis of nonpeptide mimetics of jaspamide. International Journal of Peptide and Protein Research, 1991, 38, 324-334.	0.1	20
123	Secondary Structure Prediction for the Spectrin 106-Amino Acid Segment, and a Proposed Model for Tertiary Structure. Journal of Biomolecular Structure and Dynamics, 1990, 8, 55-62.	3.5	12
124	Hemoglobin S antigelation agents based on 5-bromotryptophan with potential for sickle cell anemia. Journal of Medicinal Chemistry, 1990, 33, 3138-3142.	6.4	18
125	5-Bromo-DL-tryptophan and Protected Intermediates for Peptide Synthesis. Synthetic Communications, 1990, 20, 3459-3466.	2.1	8
126	Social Science Research. Social Studies of Science, 1989, 19, 759-762.	2.5	1

#	Article	IF	Citations
127	QSAR and molecular shape analysis of aryl-substituted alanine analogs as antigelling agents. Journal of Theoretical Biology, 1989, 141, 41-52.	1.7	3
128	Quantitative detection of rapid motions in spectrin by NMR. Life Sciences, 1989, 44, 735-740.	4.3	12
129	The design and synthesis of mimetics of peptide Î²-turns. Journal of Molecular Recognition, 1988, 1, 75-79.	2.1	40
130	Saturation-transfer electron paramagnetic resonance detection of anisotropic motion by sickle hemoglobin molecules in the polymer state. Biochemistry, 1987, 26, 1903-1909.	2.5	3
131	Electron spin-echo techniques for the study of protein motion. Journal of Magnetic Resonance, 1987, 75, 397-413.	0.5	2
132	Selective detection of rapid motions in spectrin by NMR. FEBS Letters, 1986, 197, 234-238.	2.8	19
133	Interaction of a spin-labeled phenylalanine analog with normal and sickle hemoglobins: detection of site-specific interactions through spin-label-induced proton NMR relaxation. Biochemistry, 1986, 25, 5647-5654.	2.5	7
134	CD of gels and suspensions: Apparent CD in the soret region of sickle hemoglobin gels. Biopolymers, 1986, 25, 1359-1378.	2.4	5
135	Recent Developments in Spin Label EPR Methodology for Biomembrane Studies. Current Topics in Bioenergetics, 1984, , 107-157.	2.7	10
136	Binding of a spin-labeled phenylalanine analog to sickle hemoglobin: EPR and NMR studies. FEBS Letters, 1984, 173, 259-263.	2.8	4
137	Probable binding region of small hydrophobic molecules on hemoglobin spin label-inducted nuclear magnetic relaxation. BBA - Proteins and Proteomics, 1983, 744, 193-199.	2.1	5
138	Stable isotope substituted spin labels. 2. An improved synthesis of perdeuterio-15N-(1-oxyl-2,2,6,6-tetramethyl- 4-piperidinyl)maleimide. Journal of Labelled Compounds and Radiopharmaceuticals, 1983, 20, 33-38.	1.0	5
139	Multiple motions of the spectrin-actin complex in the saturation transfer EPR time domain. Journal of Magnetic Resonance, 1983, 51, 233-244.	0.5	5
140	Temperature dependence of spin-label intensity in solutions and its implication in spin-labeled erythrocyte membrane studies. Biophysical Journal, 1983, 43, 255-257.	0.5	3
141	Saturation transfer electron paramagnetic resonance detection of sickle hemoglobin aggregation during deoxygenation. Biophysical Journal, 1983, 42, 269-274.	0.5	10
142	Models for slow anisotropic rotational diffusion in saturation transfer electron paramagnetic resonance at 9 and 35 GHz. Biochemistry, 1982, 21, 4459-4467.	2.5	32
143	A Comparison of Resolution-Enhancement Methods in Saturation-Transfer EPR. Biophysical Journal, 1982, 37, 553-557.	0.5	15
144	35-GHz (Q-band) saturation transfer electron paramagnetic resonance studies of rotational diffusion. Biochemistry, 1981, 20, 2875-2880.	2.5	30

#	Article	IF	Citations
145	Apparent hydrogen bonding by strongly immobilized spin-labels. Biochemistry, 1981, 20, 3319-3328.	2.5	41
146	Spin label detection of aggregation by deoxygenated sickle hemoglobin under non-gelling conditions. FEBS Letters, 1981, 125, 231-234.	2.8	3
147	A temperature-induced variation in the intrinsic hyperfine separation of a tightly bound nitroxide spin label. FEBS Letters, 1979, 97, 363-366.	2.8	5
148	Spin-label techniques for monitoring macromolecular rotational motion: empirical calibration under nonideal conditions. Biochemistry, 1979, 18, 378-384.	2.5	19
149	Tertiary structure variability within the quaternary states of hemoglobin: a spin label study. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 535, 193-205.	1.7	3
150	Spin label detection of intermolecular interactions in carbonmonoxy sickle hemoglobin. Biophysical Journal, 1978, 24, 517-524.	0.5	5
151	Librational motion of an "immobilized" spin label: hemoglobin spin labeled by a maleimide derivative. Biochemistry, 1978, 17, 1223-1228.	2.5	45
152	Magnetic field and temperature induced line broadening in the hyperfine-shifted proton resonances of myoglobin and hemoglobin. Journal of the American Chemical Society, 1977, 99, 1245-1250.	13.7	54
153	Possible three-dimensional models for the polypeptide backbone structure of alamethicin. Journal of Theoretical Biology, 1976, 60, 183-195.	1.7	11
154	Effects of ligands and organic phosphates on functional properties of human adult hemoglobin. Biochemistry, 1974, 13, 3653-3661.	2.5	83
155	A synthetic lecithin containing branched-chain fatty acids: Physical properties and membrane studies. Biochimica Et Biophysica Acta - Biomembranes, 1973, 291, 587-591.	2.6	19